Literature DB >> 26787285

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Elizabeth I Buchbinder1, F Stephen Hodi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787285     DOI: 10.1038/nrclinonc.2015.237

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

5.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Authors:  Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway
Journal:  Science       Date:  2015-09-10       Impact factor: 47.728

7.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

8.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

10.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

  10 in total
  24 in total

Review 1.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

2.  Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Authors:  Keehoon Jung; Takahiro Heishi; Omar F Khan; Piotr S Kowalski; Joao Incio; Nuh N Rahbari; Euiheon Chung; Jeffrey W Clark; Christopher G Willett; Andrew D Luster; Seok Hyun Yun; Robert Langer; Daniel G Anderson; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 3.  Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Authors:  Xingzhou Peng; Junjie Wang; Feifan Zhou; Qian Liu; Zhihong Zhang
Journal:  Cell Mol Life Sci       Date:  2021-05-08       Impact factor: 9.261

4.  Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.

Authors:  Chao Wang; Wujin Sun; Grace Wright; Andrew Z Wang; Zhen Gu
Journal:  Adv Mater       Date:  2016-08-25       Impact factor: 30.849

5.  STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.

Authors:  L L Bu; G T Yu; L Wu; L Mao; W W Deng; J F Liu; A B Kulkarni; W F Zhang; L Zhang; Z J Sun
Journal:  J Dent Res       Date:  2017-06-12       Impact factor: 6.116

6.  Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.

Authors:  Rui Li; Weiheng Zhao; Rui Liang; Chen Jin; Huihua Xiong
Journal:  Front Mol Biosci       Date:  2022-06-30

7.  Local delivery of checkpoints antibodies.

Authors:  Chao Wang; Yanqi Ye; Zhen Gu
Journal:  Hum Vaccin Immunother       Date:  2016-09-26       Impact factor: 3.452

8.  Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.

Authors:  Nalini Marino; Sam Illingworth; Prithvi Kodialbail; Ashvin Patel; Hugo Calderon; Rochelle Lear; Kerry D Fisher; Brian R Champion; Alice C N Brown
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

9.  Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.

Authors:  Yue Lu; Alphonsus H C Ng; Frances E Chow; Richard G Everson; Beth A Helmink; Michael T Tetzlaff; Rohit Thakur; Jennifer A Wargo; Timothy F Cloughesy; Robert M Prins; James R Heath
Journal:  Nat Commun       Date:  2021-06-29       Impact factor: 14.919

10.  Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.

Authors:  Keehoon Jung; Takahiro Heishi; Joao Incio; Yuhui Huang; Elizabeth Y Beech; Matthias Pinter; William W Ho; Kosuke Kawaguchi; Nuh N Rahbari; Euiheon Chung; Jun Ki Kim; Jeffrey W Clark; Christopher G Willett; Seok Hyun Yun; Andrew D Luster; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.